Peroxiredoxin III protein expression is associated with platinum resistance in epithelial ovarian cancer

Abstract

We investigated the association between peroxiredoxin III (PRX III) and chemotherapy resistance in ovarian cancer. Patient's specimens were taken at the time of surgery. Determination of resistance is based on whether first diagnosis of relapse occurred within 6 months after the cessation of chemotherapy. PRX III expression was immunohistochemically determined in paraffin-embedded specimens from platinum-resistant (Pt-resistant) and platinum-sensitive (Pt-sensitive) patients. The Pt-resistant group had significantly higher PRX III protein compared to the Pt-sensitive group. The two groups showed no significant differences in pathological classification and age, although they differed significantly in tissue differentiation and stage. PRX III protein was significantly higher in the Pt-resistant serous carcinomas, in moderately and poorly differentiated, and in stage III and IV ovarian cancer tissues compared to the Pt-sensitive group. PRX III may be associated with drug resistance in ovarian cancer.

Hydrogen peroxide mediated mitochondrial UNG1-PRDX3 interaction and UNG1 degradation

“…PRDX3 is a mitochondrial-specific protein with one thioredoxin domain involved in cell redox regulation and it protects enzymes from radical oxygen damage [40,45]. The expression of PRDX3 is regulated by HIF1-alpha and is associated with cell proliferation and resistance to drug treatment in cancer cells [46][47][48]. In response to peroxide treatment, PRDX1 and PRDX3 forms a complex which may mediate peroxide signal transduction [49].…”

The functional role of peroxiredoxin 3 in reactive oxygen species, apoptosis, and chemoresistance of cancer cells

“…By a review of substantial literature, we can draw the conclusion that the up-regulation of PRX3 in diverse cancers is involved in tumor progression or chemotherapeutic resistance through controlling ROS level and inhibiting ROS-induced apoptosis of the cancer cells (Whitaker et al 2013;Wang et al 2013Wang et al , 2014. Mitochondrion-specific PRX3 has been suggested to regulate cytochrome c release from mitochondria, which is a critical early step in the Fig.…”

The prognostic values of the peroxiredoxins family in ovarian cancer

“…In addition, Duan et al [60] observed that the expression of PRDX3 was significantly higher in cancer tissues than the adjacent non-cancerous tissues, and high PRDX3 levels in serous ovarian carcinoma were related to poorly differentiated cancer cells, FIGO stages III and IV, which suggests that aberrant expression of PRDX3 is significantly associated with the progression of ovarian cancer. Wang et al [61] found that PRDX3 expression was significantly higher in the platinum-resistant serous ovarian cancer, in stages III and IV, and in moderately and poorly differentiated ovarian cancer tissues compared with their platinum-sensitive counterparts, they therefore concluded that PRDX3 was associated with drug resistance in ovarian cancer. However, there are no reports concerning the prognostic value of either PRDX3 protein or mRNA in ovarian cancer.…”

“…As antioxidants, PRDXs have been shown to be related to chemotherapy drug resistance of cancers. PRDX3 expression was associated with platinum resistance in ovarian cancer, and siRNA targeting of PRDX3 triggered cisplatin–induced apoptosis in SKOV3 ovarian cancer cells through suppression of the NF–κB signaling pathway [60,61]. Furthermore, overexpression of PRDX6 attenuated cisplatin-induced apoptosis by reducing ROS levels in SKOV-3 ovarian cancer cells and led to the development of cisplatin resistance [74].…”